Danaher to Acquire Masimo for $180/Share Cash

Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation, a specialty diagnostics provider focused on pulse oximetry and patient monitoring in acute care settings. Under the terms, Danaher will acquire all outstanding Masimo common shares for $180 per share in cash.

The transaction implies an enterprise value of approximately $9.9 billion, including assumed indebtedness and net of acquired cash. Danaher expects the deal to be accretive to adjusted diluted net earnings per share by $0.15 to $0.20 in the first full year and about $0.70 in the fifth full year after closing. The acquisition is expected to close in the second half of 2026, subject to regulatory clearances and Masimo shareholder approval.